<DOC>
	<DOCNO>NCT02924311</DOCNO>
	<brief_summary>The main objective observational study describe outcome , monitor treatment pattern patient diabetic macular edema routine clinical practice either treatment naïve patient previously treat patient . The total study population evaluate well two subgroup ( previously treat patient treatment naïve patient ) . This study designate answer French Health Authority ( HAS Haute Autorité de Santé ) requirement .</brief_summary>
	<brief_title>Routine Clinical Practice Use Intravitreal Aflibercept Treatment Patients With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>Man woman age 18 year Patient diagnose visual impairment due diabetic macular disease ( define HAS ( Haute Autorité de Santé ) recommendation : baseline visual acuity less equal 5/10 ) Patients decision treat intravitreal aflibercept make independently patient enrollment study Patient diagnose type 1 2 diabetes mellitus Patient give appropriate information study give his/her write , informed consent Patient retinal disease time inclusion Patients currently treat intravitreal aflibercept . This study include patient new intravitreal aflibercept Systemic use anti / pro VEGF therapy ( VEGF : Vascular Endothelial Growth Factor ) Patient take part interventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
</DOC>